Cannabis Sativa, Inc., through its subsidiaries, focuses on the research, development and commercialization of pharmaceutical products derived from the cannabis plant. The company maintains a proprietary library of natural and synthetic cannabinoids and is advancing a range of preclinical and early-stage clinical programs targeting central nervous system, oncology and rare disease indications. Its efforts aim to leverage the therapeutic potential of cannabinoid molecules to address unmet medical needs.
In pursuit of its research objectives, Cannabis Sativa collaborates with academic institutions, contract research organizations and biopharmaceutical partners. The company’s strategy includes licensing and co-development agreements to support the translation of its cannabinoid formulations into clinical candidates. By combining traditional botanical extracts with novel synthetic analogs, it seeks to optimize pharmacological profiles, bioavailability and delivery mechanisms.
Headquartered in Mississauga, Ontario, Cannabis Sativa conducts operations across North America, utilizing specialized extraction and analytical platforms to ensure the quality, purity and consistency of its cannabinoid compounds. The company’s management team comprises professionals with backgrounds in pharmacology, drug development and regulatory affairs, providing the expertise needed to navigate complex clinical and commercialization pathways. As a publicly traded entity on the OTC Markets (OTCMKTS: CBDS), it aims to advance its pipeline while exploring strategic partnerships and licensing opportunities worldwide.
AI Generated. May Contain Errors.
Free CBDS Stock Alerts